NeuroVenti introduces CDRO services at the KSBNS's regular international conference and the KSNS's workshop 

From October 15 to 18, the 27th KSBNS 2024 in conjunction with the APSN was held at Gyeongju HICO, and from October 17 to 18, the 46th workshop of the 2024 Korea Non-clinical Trial Research Association was held at Gyeongju Lahan Select Hotel, introducing Neuroventi's non-clinical CDRO service for brain diseases.

Neuroventi's non-clinical CDRO service for brain diseases is a total service that adds business know-how to the non-clinical CRO service specialized in CNS diseases based on Neuroventi's technological prowess in the field of brain diseases that it has honed over the years to its existing CRO service. Based on its long-term efforts in developing new drugs related to brain development disorders using various animal models of brain diseases, it is proud to say that it is the best in Korea in terms of technological prowess and expertise in the field of 'central nervous system diseases'.

In particular, Neuroventi recently received approval from the Ministry of Food and Drug Safety for the Phase 2 clinical trial plan (IND) for ‘NV01-A02’, a new drug being developed for the treatment of autism spectrum disorder (ASD), and the Phase 2 clinical trial is scheduled to be conducted as early as the end of this year at 7 domestic medical institutions, including Bundang Seoul National University Hospital, targeting 105 children aged 6 to 15 years old diagnosed with ASD. Neuroventi CEO Shin Chan-young said, “We have been preparing for Phase 2 clinical trials with sufficient scientific evidence for several years, so we are confident in the success of the clinical trial, and our goal is to shorten the clinical trial period even more,” and attention is pouring from all walks of life on the successful conduct of the Phase 2 clinical trial, which will begin in the second half of this year.

info@neuroventi.com